PE20221910A1 - Derivados de pirazolilo utiles como agentes anticancerigenos - Google Patents

Derivados de pirazolilo utiles como agentes anticancerigenos

Info

Publication number
PE20221910A1
PE20221910A1 PE2022001123A PE2022001123A PE20221910A1 PE 20221910 A1 PE20221910 A1 PE 20221910A1 PE 2022001123 A PE2022001123 A PE 2022001123A PE 2022001123 A PE2022001123 A PE 2022001123A PE 20221910 A1 PE20221910 A1 PE 20221910A1
Authority
PE
Peru
Prior art keywords
compound
anticancer agents
derivatives useful
atropisomer
optionally substituted
Prior art date
Application number
PE2022001123A
Other languages
English (en)
Inventor
Simona Cotesta
Marc Gerspacher
Catherine Leblanc
Edwige Liliane Jeanne Lorthiois
Bo Liu
Rainer Machauer
Robert Mah
Christophe Mura
Pascal Rigollier
Nadine Schneider
Stefan Stutz
Andrea Vaupel
Nicolas Warin
Rainer Wilcken
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20221910A1 publication Critical patent/PE20221910A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Refiere a un compuesto de formula (I), o un estereoisomero, o un atropisomero, o una sal farmaceuticamente aceptable del mismo o de un atropisomero, en donde, A se selecciona de un anillo heteroarilo de 8-10 miembros que comprende N, O, S o un anillo heterobiciclico parcialmente saturado de 8-10 miembros seleccionados de N, O, S y S(=O)2., entre otros; B se selecciona de B1, que es arilo C6-10 opcionalmente sustituido con 1, 2, 3 o 4 RBa, y de B2, que es un heteroarilo de 6-13 miembros con 1 - 3 atomos de nitrogeno y opcionalmente sustituido con 1, 2, 3 o 4 RBb; C se selecciona de -CH(CN)-CH3, -CH(OH)-CH3, entre otros; L se selecciona de un grupo que comprende RL, seleccionado de -CH2-CN, -CH2-OH, entre otros, y G , que representa el punto de union a G, en donde R2,R3,R4,R5,R6 Y R7 son hidrogeno, metilo, entre otros. Asimismo, se refiere a metodos para fabricar dicho compuesto y su uso para el tratamiento de un cancer o de un tumor solido, mediante una combinacion de agentes farmacologicamente activos y una composicion farmaceutica que comprende dicho compuesto.
PE2022001123A 2019-12-20 2020-12-17 Derivados de pirazolilo utiles como agentes anticancerigenos PE20221910A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951400P 2019-12-20 2019-12-20
PCT/CN2020/125425 WO2021120890A1 (en) 2019-12-20 2020-10-30 Pyrazolyl derivatives useful as anti-cancer agents
PCT/IB2020/062144 WO2021124222A1 (en) 2019-12-20 2020-12-17 Pyrazolyl derivatives useful as anti-cancer agents

Publications (1)

Publication Number Publication Date
PE20221910A1 true PE20221910A1 (es) 2022-12-23

Family

ID=76477081

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001123A PE20221910A1 (es) 2019-12-20 2020-12-17 Derivados de pirazolilo utiles como agentes anticancerigenos

Country Status (22)

Country Link
US (1) US11702409B2 (es)
EP (2) EP4076662B1 (es)
JP (1) JP2023506841A (es)
KR (1) KR20220114064A (es)
CN (1) CN114929342A (es)
AR (1) AR120855A1 (es)
AU (1) AU2020410531B2 (es)
CA (1) CA3165148A1 (es)
CL (1) CL2022001625A1 (es)
CO (1) CO2022008344A2 (es)
CR (1) CR20220281A (es)
DK (1) DK4076662T3 (es)
DO (1) DOP2022000124A (es)
EC (1) ECSP22047876A (es)
FI (1) FI4076662T3 (es)
IL (1) IL293893A (es)
JO (1) JOP20220155A1 (es)
MX (1) MX2022007350A (es)
PE (1) PE20221910A1 (es)
TW (1) TW202136241A (es)
UY (1) UY38990A (es)
WO (2) WO2021120890A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292438A (en) 2019-10-28 2022-06-01 Merck Sharp & Dohme Small molecules that inhibit the g12c mutant of kras
CN116034106A (zh) 2020-06-02 2023-04-28 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
KR20230067635A (ko) 2020-09-15 2023-05-16 레볼루션 메디슨즈, 인크. 암의 치료에서 ras 억제제로서 인돌 유도체
BR112023007912A2 (pt) * 2020-10-30 2024-01-02 Novartis Ag Formas cristalinas de um composto inibidor de kras g12c
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
KR20230127256A (ko) * 2020-12-22 2023-08-31 노파르티스 아게 Kras g12c 억제제를 포함하는 약제학적 조합물 및 암의치료를 위한 kras g12c 억제제의 용도
WO2022133731A1 (en) * 2020-12-22 2022-06-30 Novartis Ag Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
CR20230570A (es) 2021-05-05 2024-01-22 Revolution Medicines Inc Inhibidores de ras
CN117337193A (zh) * 2021-05-19 2024-01-02 基因泰克公司 组合疗法
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
WO2022269508A1 (en) * 2021-06-23 2022-12-29 Novartis Ag Pyrazolyl derivatives as inhibitors of the kras mutant protein
CN117677398A (zh) 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
CA3224341A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
US20230203062A1 (en) 2021-11-24 2023-06-29 Genentech, Inc. Therapeutic compounds and methods of use
WO2023097195A1 (en) 2021-11-24 2023-06-01 Genentech, Inc. Therapeutic indazole compounds and methods of use in the treatment of cancer
WO2023099592A1 (en) * 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
WO2023122662A1 (en) 2021-12-22 2023-06-29 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
TW202332434A (zh) * 2022-01-31 2023-08-16 瑞士商諾華公司 可用作抗癌劑的吡唑基衍生物之合成方法
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023199180A1 (en) 2022-04-11 2023-10-19 Novartis Ag Therapeutic uses of a krasg12c inhibitor
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024040131A1 (en) 2022-08-17 2024-02-22 Treeline Biosciences, Inc. Pyridopyrimidine kras inhibitors
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer
CN116478141B (zh) * 2023-06-20 2023-10-24 药康众拓(江苏)医药科技有限公司 氘代kras抑制剂药物及用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1199600A (en) * 1998-10-02 2000-04-26 Board Of Trustees Of The University Of Illinois, The Estrogen receptor ligands
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
US20080171755A1 (en) 2004-08-31 2008-07-17 Wen-Cherng Lee Pyrimidinylpyrazoles as Tgf-Beta Inhibitors
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
ES2525217T3 (es) * 2005-06-27 2014-12-19 Exelixis Patent Company Llc Moduladores de LXR basados en imidazol
WO2007105058A2 (en) 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
AU2008276521B2 (en) * 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
AP2010005167A0 (en) * 2007-08-01 2010-02-28 Pfizer Pyrazole compounds and their use as RAF inhibitors
MX2011000738A (es) * 2008-07-24 2011-02-23 Nerviano Medical Sciences Srl 3,4-diarilpirazoles como inhibidoers de proteina cinasa.
US20120010186A1 (en) * 2009-03-23 2012-01-12 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US9114137B2 (en) 2010-08-03 2015-08-25 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
EP2836482B1 (en) 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
EP2970121B1 (en) 2013-03-15 2017-12-13 Araxes Pharma LLC Covalent inhibitors of kras g12c
KR20160076519A (ko) * 2013-10-10 2016-06-30 아락세스 파마 엘엘씨 Kras g12c 억제제
TW201702232A (zh) 2015-04-10 2017-01-16 亞瑞克西斯製藥公司 經取代之喹唑啉化合物及其使用方法
EP3356339A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
ES2863873T3 (es) 2016-05-18 2021-10-11 Mirati Therapeutics Inc Inhibidores de KRAS G12C
CN110312711A (zh) 2016-10-07 2019-10-08 亚瑞克西斯制药公司 作为ras抑制剂的杂环化合物及其使用方法
CN108069955B (zh) * 2016-11-14 2021-04-06 江苏恒瑞医药股份有限公司 3-吡啶基-4-苯并噻唑基吡唑类衍生物、其制备方法及其在医药上的应用
BR112019008516A2 (pt) * 2016-11-14 2019-07-09 Jiangsu Hengrui Medicine Co derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo
RS62456B1 (sr) 2016-12-22 2021-11-30 Amgen Inc Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva
CN110382483A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的n-杂环化合物及其使用方法
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
US11059819B2 (en) 2017-01-26 2021-07-13 Janssen Biotech, Inc. Fused hetero-hetero bicyclic compounds and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
JOP20190186A1 (ar) 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
CA3063440A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras
EP3710439B1 (en) * 2017-11-15 2023-02-15 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2019136147A1 (en) * 2018-01-03 2019-07-11 The Board Of Trustees Of The University Of Illinois Toll-like receptor signaling inhibitors
KR20200126393A (ko) * 2018-02-23 2020-11-06 사뮤메드, 엘엘씨 5-헤테로아릴 치환된 인다졸-3-카복사미드 및 그의 제조 및 용도
EP3788038B1 (en) * 2018-05-04 2023-10-11 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019217691A1 (en) * 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
US11096939B2 (en) 2018-06-01 2021-08-24 Amgen Inc. KRAS G12C inhibitors and methods of using the same

Also Published As

Publication number Publication date
IL293893A (en) 2022-08-01
US20220363670A1 (en) 2022-11-17
JOP20220155A1 (ar) 2023-01-30
US11702409B2 (en) 2023-07-18
JP2023506841A (ja) 2023-02-20
UY38990A (es) 2021-07-30
DOP2022000124A (es) 2022-07-31
WO2021124222A1 (en) 2021-06-24
ECSP22047876A (es) 2022-07-29
EP4076662A1 (en) 2022-10-26
FI4076662T3 (fi) 2024-04-24
CO2022008344A2 (es) 2022-06-30
AU2020410531B2 (en) 2024-03-07
AR120855A1 (es) 2022-03-23
TW202136241A (zh) 2021-10-01
MX2022007350A (es) 2022-07-19
CN114929342A (zh) 2022-08-19
WO2021120890A1 (en) 2021-06-24
CA3165148A1 (en) 2021-06-24
CR20220281A (es) 2022-07-01
AU2020410531A1 (en) 2022-07-28
EP4344702A2 (en) 2024-04-03
KR20220114064A (ko) 2022-08-17
EP4076662B1 (en) 2024-01-31
EP4344702A3 (en) 2024-04-10
CL2022001625A1 (es) 2023-03-24
DK4076662T3 (da) 2024-04-22

Similar Documents

Publication Publication Date Title
PE20221910A1 (es) Derivados de pirazolilo utiles como agentes anticancerigenos
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
MX2022008066A (es) Compuestos triciclicos sustituidos.
CL2021002883A1 (es) Moduladores de thr-ß y métodos de uso de estos
PE20230249A1 (es) Compuestos de heteroarilo biciclicos y usos de estos
AR074876A1 (es) Derivados de indol-pirimidina para tratar cancer
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
RU2012140961A (ru) ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
CO2022002729A2 (es) Métodos de tratamiento del cáncer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrógenos
UY27503A1 (es) Nuevos derivados de piperazina
PE20212303A1 (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer
AR053364A1 (es) Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis
AR126701A1 (es) Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos
PE20212329A1 (es) Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cancer
PE20211769A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
AR039190A1 (es) Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto
AR126854A1 (es) Compuestos macrocíclicos para el tratamiento de cáncer
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
PE20200727A1 (es) Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso
CL2022000892A1 (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
PE20232044A1 (es) Compuestos heterociclicos de heteroarilo y usos de los mismos